Takeda introduces Edarbyclor drug in US - Pharmaceutical Business Review
Takeda introduces Edarbyclor drug in USPharmaceutical Business ReviewIn a phase 3 clinical trial, Edarbyclor (40/25 mg) was found to reduce systolic blood pressure compared to the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide at its maximum dose (40/25 mg).
Daiichi Sankyo net profit dips by 78% in first nine months - pharmabiz.com
Daiichi Sankyo net profit dips by 78% in first nine monthspharmabiz.
Forest Laboratories, Inc. Reports Fiscal Year Third Quarter 2012 Earnings Per ... - MarketWatch (press release)
Forest Laboratories, Inc.
Congress MP terms proposed pharma policy incomplete and disappointing - pharmabiz.com
Congress MP terms proposed pharma policy incomplete and disappointingpharmabiz.
Takeda gains approval for hypertension drug Azilva in Japan - PMLiVE
Takeda gains approval for hypertension drug Azilva in JapanPMLiVEPrior studies had also shown it to be superior to valsartan, developed and sold by Novartis as Diovan, and Daiichi Sankyo's Benicar/Olmetec (olmesartan).